Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)-Reference-Cited by-同舟云学术

Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)

Published:2020-10-27 Issue:1 Volume:96 Page:69-79
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Polverelli Nicola¹^ORCID,Mauff Katya²,Kröger Nicolaus³,Robin Marie⁴^ORCID,Beelen Dietrich⁵,Beauvais David⁶,Chevallier Patrice⁷,Mohty Mohamad⁸⁹¹⁰,Passweg Jakob¹¹,Rubio Marie Thérèse¹²,Maertens Johan¹³,Finke Jürgen¹⁴,Bornhäuser Martin¹⁵,Vrhovac Radovan¹⁶,Helbig Grzegorz¹⁷,Mear Jean‐Baptiste¹⁸,Castagna Luca¹⁹,Reményi Péter²⁰,Angelucci Emanuele²¹^ORCID,Karakasis Dimitrios²²,Rifòn Jose²³,Sirait Tiarlan²,Russo Domenico¹,Wreede Liesbeth²⁴,Czerw Tomasz²⁵^ORCID,Hernández‐Boluda Juan Carlos²⁶^ORCID,Hayden Patrick²⁷,McLornan Donal²⁸,Yakoub‐Agha Ibrahim²⁹

Affiliation:

1. Unit of Blood Diseases and Stem Cells Transplantation, Department of Clinical and Experimental Sciences University of Brescia ASST Spedali Civili of Brescia

2. Leiden Data Office LUMC Leiden Netherlands

3. Department of Hematology University Hospital Eppendorf Hamburg Germany

4. Department of Hematology Hôpital Saint‐Louis, APHP Paris France

5. Department of Hematology University Hospital of Essen Essen Germany

6. Department of Hematology CHU Lille Lille France

7. Department of Hematology CHU Nantes Nantes France

8. Sorbonne University Paris France

9. Service d'Hématologie Clinique et Thérapie cellulaire Hopital Saint‐Antoine Paris France

10. INSERM Paris France

11. Department of Hematology University Hospital Basel Basel Switzerland

12. Department of Hematology CHRU BRABOIS Vandoeuvre Les Nancy France

13. Department of Hematology University Hospital Gasthuisberg Leuven Belgium

14. Department of Hematology University of Freiburg Freiburg Germany

15. Department of Hematology University Hospital Dresded Dresden Germany

16. Department of Hematology University Hospital Center Rebro Zagreb Croatia

17. Department of Hematology Silesian Medical Academy Katowice Poland

18. Department of Hematology Centre Hospitalier Universitaire de Rennes Rennes France

19. Department of Hematology Centre de Recherche en Cancérologie de Marseille Marseille France

20. Department of Hematology Dél‐pesti Centrumkórház Budapest Hungary

21. Hematology and Transplant Center IRCCS Ospedale Policlinico San Martino Genoa Italy

22. Department of Hematology Evangelismos Hospital Athens Greece

23. Department of Hematology Clínica Universitaria de Navarra Pamplona Spain

24. Department of Biomedical Data Sciences LUMC Leiden Netherlands

25. Department of Bone Marrow Transplantation and Onco‐Hematology Maria Sklodowska‐Curie National Research Institute of Oncology Gliwice Poland

26. Department of Hematology Hospital Clínico Universitario de Valencia Valencia Spain

27. Department of Hematology St. James's Hospital Dublin Ireland

28. Department of Hematology Guy's and St Thomas' NHS Foundation Trust and University College London Hospitals London UK

29. CHU de Lille Université de Lille Lille France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26020

Reference55 articles.

1. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

2. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

3. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

4. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis

5. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study;Guardiola P;Blood.,1999

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation;Bone Marrow Transplantation;2024-02-06

2. Persistent hypersplenism following successful hematopoietic stem cell transplantation: unraveling the cellular components of extramedullary residual disease and donor hematopoiesis—a case report;Frontiers in Hematology;2024-01-09

3. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group;The Lancet Haematology;2024-01

4. THE ITALIAN MULTICENTRIC RANDOMIZED OPTKIMA TRIAL ON FIXED VS PROGRESSIVE INTERMITTENT TKI THERAPY IN CML ELDERLY PATIENTS: 3-YEARS OF MOLECULAR RESPONSE AND QUALITY OF LIFE MONITORING AFTER COMPLETING THE TREATMENT PLAN.;Clinical Lymphoma Myeloma and Leukemia;2024-01

5. Are transplant indications changing for myelofibrosis?;Hematology;2023-12-08